SAB Biotherapeutics Warrant
SABSW
9 hedge funds and large institutions have $66.3K invested in SAB Biotherapeutics Warrant in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
197% more capital invested
Capital invested by funds: $22.3K → $66.3K (+$44K)
2.81% more ownership
Funds ownership: 6.72% → 9.53% (+2.8%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$32.5K |
| 2 |
Walleye Trading
New York
|
+$1.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$98 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
-$15.7K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$920 |
| 3 |
Walleye Capital
New York
|
-$837 |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$414 |
| 5 |
CS
Clear Street
New York
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $40.6K | +$32.5K | +539,588 | New |
|
2
Morgan Stanley
New York
| $11K | – | – | – |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| $7.02K | -$920 | -15,255 | -14% |
|
|
HWM
4
HB Wealth Management
Atlanta,
Georgia
| $3.87K | -$15.7K | -259,999 | -84% |
|
|
5
Walleye Trading
New York
| $2.92K | +$1.4K | +23,258 | +150% |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $651 | -$414 | -6,864 | -44% |
|
|
7
UBS Group
Zurich,
Switzerland
| $122 | +$98 | +1,633 | New |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $80 | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4 | – | – | – |
|
|
10
Walleye Capital
New York
| – | -$837 | -23,258 | Closed |
|
|
CS
11
Clear Street
New York
| – | -$7 | -200 | Closed |
|
SABSW Hedge Fund Activity: Q4 2024 in Review
9 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2024, worth a combined $66.3K — up 197% from $22.3K a quarter earlier.
Fund positioning in SABSW was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was LMR Partners, opening a new position worth an estimated $32.5K. The largest seller was HB Wealth Management, cutting an estimated $15.7K.
- 9 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $66.3K of SAB Biotherapeutics Warrant stock for Q4 2024, up 197% quarter-over-quarter.
- 2 funds opened new SAB Biotherapeutics Warrant positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2024 was LMR Partners, an estimated $32.5K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2024 was HB Wealth Management, an estimated $15.7K sold.
Based on aggregated 13F filings for Q4 2024.